Cullinan Therapeutics, Inc. CGEM Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$221.04M-23.7% | -$219.88M-31.2% | -$216.81M-49.0% | -$206.76M-43.5% | -$178.74M-33.1% | ||
| $314K+2.6% | $311K+1.6% | $309K+1.0% | $306K-1.3% | $306K-2.5% | ||
| $34.28M-12.0% | $36.04M-4.7% | $38.36M+7.4% | $38.33M+12.7% | $38.97M+24.1% | ||
| -$178.64M-18.9% | -$175.75M-21.0% | -$174.27M-37.4% | -$171.53M-35.3% | -$150.21M-23.6% | ||
| —— | —— | —— | —— | —— | ||
| $175.6M— | $179.99M— | —— | —— | —— | ||
| $1.47M-99.4% | $1.09M-99.6% | $1.96M-99.3% | $3.28M-98.8% | $265.1M+562% | ||
| —— | —— | $1.25M— | -$42.2M— | $2.43M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Cullinan Therapeutics, Inc. generate?
- Cullinan Therapeutics, Inc. (CGEM) generated -$178.6M in operating cash flow over the trailing twelve months.
- What is Cullinan Therapeutics, Inc.'s free cash flow?
- After $11.0K of capital expenditures, Cullinan Therapeutics, Inc.'s free cash flow was -$145.2M over the trailing twelve months, down 19.4% year over year.
- Where does Cullinan Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Cullinan Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.